New Key Statistics Module, Z-Score and F-Score
NAS:XLO Key Ratios
| Market Cap $ M | 39.66 |
| Enterprise Value $ M | -26.61 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.17 |
| Price/Sales | 21.74 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 2.00 |
| EPS (TTM) $ | -2.11 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.41 |
| EV-to-EBITDA | 0.42 |
| PEG | -- |
| Shares Outstanding M | 43.95 |
| Net Margin (%) | -2,780.27 |
| Operating Margin % | -2,830.04 |
| Pre-tax Margin (%) | -2,780.27 |
| Quick Ratio | 2.02 |
| Current Ratio | 2.02 |
| ROA % (ttm) | -81.18 |
| ROE % (ttm) | -151.77 |
| ROIC % (ttm) | -241.44 |
| Dividend Yield % | -- |
| Altman Z-Score | -6.99 |
XLO Number of Guru Trades
XLO Volume of Guru Trades
Gurus Latest Trades with NAS:XLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:XLO is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Xilio Therapeutics Inc Insider Transactions
No Available Data
News about NAS:XLO
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers